ABSTRACT
Objective To observe the effects of buyang huanwu decoction combined with sarpogrelate hydrochloride in the treatment of elderly diabetes mellitus associated with lower extremity arteriosclerosis obliterans(ASO). Methods 102 patients with diabetic lower limb ASO enrolled in Tongde hospital from December 2014 to December 2016 were divided into the experimental group and the control group according to the treatment way, with 51 cases in each group. The control group was treated with sarpogrelate hydrochloride, the experimental group was treated with buyang huanwu decoction based on the basis of control group, both groups was treated for two months. The clinical curative effect, the dorsalis pedis artery blood flow, ankle brachial index, claudication distance, and adverse reactions occur was compared and observed between two groups. Results The total effective rate of the experimental group was 92.16% higher than 76.47% of the control group (P<0.05). The dorsalis pedis artery blood flow, ankle brachial index, claudication distance of experimental group was higher than the control group (P<0.05). There was no significant difference in adverse reactions between the two groups. Conclusion The effect of buyang huanwu decoction joint sarpogrelate hydrochloride in the treatment elderly diabetes ASO, can relieve body blood, blood fat, blood sugar state, promote patient recovery.
ABSTRACT
Objective To observe the effects of buyang huanwu decoction combined with sarpogrelate hydrochloride in the treatment of elderly diabetes mellitus associated with lower extremity arteriosclerosis obliterans(ASO). Methods 102 patients with diabetic lower limb ASO enrolled in Tongde hospital from December 2014 to December 2016 were divided into the experimental group and the control group according to the treatment way, with 51 cases in each group. The control group was treated with sarpogrelate hydrochloride, the experimental group was treated with buyang huanwu decoction based on the basis of control group, both groups was treated for two months. The clinical curative effect, the dorsalis pedis artery blood flow, ankle brachial index, claudication distance, and adverse reactions occur was compared and observed between two groups. Results The total effective rate of the experimental group was 92.16% higher than 76.47% of the control group (P<0.05). The dorsalis pedis artery blood flow, ankle brachial index, claudication distance of experimental group was higher than the control group (P<0.05). There was no significant difference in adverse reactions between the two groups. Conclusion The effect of buyang huanwu decoction joint sarpogrelate hydrochloride in the treatment elderly diabetes ASO, can relieve body blood, blood fat, blood sugar state, promote patient recovery.
ABSTRACT
Aim To investigate the influence of sarpog-relate hydrochloride (SH)on the pharmacokinetic pro-file of dextromethorphan (DM),the typical substrate of CYP2D1 /2,in rats when they were administered co-instantaneously.Methods A total of 1 2 SD rats were randomly divided into two groups:the control group (DM,1 0 mg·kg-1 )and the sarpogrelate group (SH, 1 0 mg·kg-1 ;DM,1 0 mg·kg-1 ),which received in-tragastric administration.Plasma samples were collected immediately before and at different time points after drug administration.A LC-MS /MS method was used to determine the concentrations of DM in rat plasma. Pharmacokinetic parameters were analyzed using Drug and Statistics (DAS 2.0).Results There were signif-icant differences in the pharmacokinetic parameters of DM,including T1 2 (2.49 h ±0.93 h vs 1 .47 h ±0.20 h,P <0.05 ),Cmax (325.7 μg·L -1 ±1 33.2 μg· L -1 vs 1 04.5μg·L -1 ±52.4 μg·L -1 ,P <0.05), AUC0 -t(785.5 μg·L -1 ·h ±451 .9 μg·L -1 ·h vs 244.8 μg·L -1 ·h ±1 68.3μg·L -1 ·h,P <0.05) and AUC0 -∞(804.7 μg·L -1 ·h ±445.6 μg·L -1 ·h vs 251 .4 μg·L -1 ·h ±1 73.4 μg·L -1 ·h,P<0.05 )between the two groups.Conclusion SH could significantly inhibit the elimination of DM,the substrate of CYP2D1 /2 in rats.
ABSTRACT
Objective To evaluate the impact of sarpogrelate on the in-stent restenosis (ISR) after percutaneous transluminal angioplasty (PTA) in peripheral arterial diseases (PAD).Methods PAD patients who had PTA for the first time were divided into two groups receiving respectively clopidogrel and aspirin (clopidogrel group) or sarpogrelate and aspirin (sarpogrelate group).Vascular ultrasonography was performed at 6 months after PTA in all patients to evaluate the degree of ISR.Results 62 patients finished the follow-up visits as required.The in-stent restenosis in the sarpogrelate group and clopidogrel group was 7.0％ vs.18.1％ (P =0.036),the peak systolic velocity ratio was 1.34 vs.2.08 (P =0.010) and the cases of ISR was 1 vs.10 (P =0.005) respectively.No patients reported serious adverse events.Conclusions Sarpogrelate combined with aspirin is safe and effective.Compare with clopidogrel and aspirin,sarpogrelate and aspirin can significantly reduce the rate of ISR after PTA and the intimal proliferation in the stent.
ABSTRACT
Objective To evaluate the clinical efficacy of oral Sarpogrelate hydrochloride in the treatment of chronic arterial ischemia of the lower extremities.Methods In this study 892 patients,who suffered from arteriosclerosis (ASO) or thromboangiitis obliterans ( TAO ) or diabetic foot ( DF ),with symptoms of intermittent claudication, sensation of cold, pain, ulcer, and without a history of vasotransplantation or bypass grafting or interventional therapy, were treated by taking Sarpogrelate hydrochloride tablets 100 mg tid for consecutive 8 weeks.The improvement rate of concomitant symptoms and the total effective rate of ASO, TAO, DF were evaluated.Drug adverse reaction were recorded.Results The improvement rate of intermittent claudication,sensation of cold,pain and ulcer were 96.9％,97.1％,89.0％ and 86.9％ respectively.The total effective rate for ASO,TAO,DF was 83.5％.A total of 81 cases (9.1％) reported mild side effects,including 7 patients with mild rash after 2- 5 days' medication,21 patients with mild nausea and 53 patients with stomach discomfort after 1 - 2 days' medication.Symptoms were managed conservatively without discontinuing taking sarpogrelate hydrochloride.Conclusions Sarpogrelate hydrochloride oral is a safe and effective therapy for chronic arterial ischemia diseases of the lower extremities.
ABSTRACT
OBJECTIVE: To establish a method for the determination of the dissolution of sarpogrelate hydrochloride tablets. METHODS: The dissolution of sarpogrelate hydrochloride tablets was determined by UV spectrophotometry with 0.1mol?L-1 hydrochloric acid as solvent at a rotation speed of 100r?min-1. The sampling time was 30min and the detection wavelength was set at 273nm. RESULTS: The linear range of sarpogrelate hydrochloride together was 3～30?g?mL-1(r=0.999 7) and the average recovery was 100%～100.35%, RSD=0.73%. The dissolutions of three batches of samples were all above 90%. CONCLUSION: The method is simple, accurate and reliable, and it can be used for the determination of the dissolution of sarpogrelate hydrochloride tablets.